The first pass through the liver
When you swallow a tablet, the absorbed drug does not go straight into general circulation. Blood from the gut drains first into the liver. So before a drug ever reaches the rest of the body, the liver gets a chance to metabolize it. This is the first-pass effect (or first-pass metabolism).
For some drugs this first pass removes a large fraction of the dose. The portion the liver removes is captured by the hepatic extraction ratio: a high-extraction drug loses most of its oral dose before it can act. The result is low oral bioavailability — only a small share of what you swallowed reaches the circulation intact.
Prodrugs: inactive on purpose
Metabolism is usually something a drug must survive. But chemists sometimes turn it into an advantage by designing a prodrug — a molecule that is inactive as swallowed and only becomes the working drug after the body metabolizes it. The metabolism step is not a loss; it is the activation switch.
- Improve absorption: a prodrug can be made more lipophilic to cross the gut wall, then converted to the active form inside.
- Mask an unpleasant property: hide a bitter taste or local irritation until the drug is past the stomach.
- Target a site: design activation to happen mainly where it is needed, sparing the rest of the body.
Active metabolites: the effect outlives the parent
Even an ordinary, fully active drug can produce an active metabolite — a product that still hits the target. Sometimes the metabolite is weaker, sometimes equal, sometimes longer-lasting than the parent. When the metabolite has a longer half-life, the drug's clinical effect can persist well after the parent has been cleared.
This matters clinically. Two drugs from the same class can feel very different simply because one leaves a long-lived active metabolite behind. And in kidney impairment, an active metabolite that the kidney normally clears can accumulate and cause toxicity even when the parent drug looks well controlled.